Ligusticum cycloprolactam inhibits IL-1β-induced apoptosis and inflammation of rat chondrocytes via HMGB1/TLR4/NF-κB signaling pathway

• Published in: Zhongguo zhongyao zazhi Vol. 49; no. 4; p. 1007
• Main Authors: Qi, Xin, Chen, Xin, An, Wen-Bo, Xu, Zhi-Ming, Wang, Duo-Xian, Luo, Peng-Fei, Chen, Yi-Xin, Ma, Jiao-Jiao, Hu, Zi-Yang, Qi, Wei, Liu, Jian-Jun, Liu, Jun-Xi
• Format: Journal Article
• Language: Chinese
• Published: China 01.02.2024
• Subjects: Animals; Apoptosis; bcl-2-Associated X Protein - metabolism; Caspase 3 - metabolism; Chondrocytes; Cyclooxygenase 2 - genetics; Cyclooxygenase 2 - metabolism; Dinoprostone; HMGB1 Protein - genetics; HMGB1 Protein - metabolism; HMGB1 Protein - pharmacology; Humans; Inflammation - metabolism; Interleukin-1beta - genetics; Interleukin-1beta - metabolism; Ligusticum; Myeloid Differentiation Factor 88 - metabolism; NF-kappa B - genetics; NF-kappa B - metabolism; Osteoarthritis - drug therapy; Osteoarthritis - genetics; Rats; RNA, Messenger - metabolism; Signal Transduction; Toll-Like Receptor 4 - genetics; Toll-Like Receptor 4 - metabolism; Tumor Necrosis Factor-alpha - metabolism; inflammatory response; apoptosis; chondrocytes; HMGB1/TLR4/NF-κB signaling pathway; osteoarthritis; ligusticum cycloprolactam(LIGc)
• ISSN: 1001-5302
• DOI: 10.19540/j.cnki.cjcmm.20230904.401

Chondrocytes are unique resident cells in the articular cartilage, and the pathological changes of them can lead to the occurrence of osteoarthritis(OA). Ligusticum cycloprolactam(LIGc) are derivatives of Z-ligustilide(LIG), a pharmacodynamic marker of Angelica sinensis, which has various biological functions such as anti-inflammation and inhibition of cell apoptosis. However, its protective effect on chondrocytes in the case of OA and the underlying mechanism remain unclear. This study conducted in vitro experiments to explore the molecular mechanism of LIGc in protecting chondrocytes from OA. The inflammation model of rat OA chondrocyte model was established by using interleukin-1β(IL-1β) to induce. LIGc alone and combined with glycyrrhizic acid(GA), a blocker of the high mobility group box-1 protein(HMGB1)/Toll-like receptor 4(TLR4)/nuclear factor-kappa B(NF-κB) signaling pathway, were used to intervene in the model, and the therapeutic effects were systematically evaluated. The viability of chondrocytes t